Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cellogen CAR-T therapy
- Development stage
- Unknown
- Lead developer
- Cellogen Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Cellogen Therapeutics' CAR-T cell therapy is an autologous, next-generation chimeric antigen receptor T-cell (CAR-T) program targeting hematological malignancies, specifically leukemia and lymphoma. Developed by the Delhi-based biotech Cellogen Therapeutics with strategic investment from NATCO Pharma, the platform includes bi-specific, third-generation, and fourth-generation CAR-T constructs. The lead candidate is a bispecific, third-generation CAR-T therapy designed to improve efficacy and reduce escape mechanisms compared to traditional single-target CAR-Ts. The therapy involves genetically engineering a patient's own T cells to express receptors that identify and eliminate cancer cells. As of early 2024, the company was preparing to initiate Phase 1 clinical trials, focusing on providing affordable and accessible treatment options.
- Other names
- Cellogen bispecific CAR-TCellogen third-generation CAR-TCellogen fourth-generation CAR-T
Beyond the preview
Go deeper on Cellogen CAR-T therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellogen CAR-T therapy.